Rituximab as therapy for refractory polymyositis and dermatomyositis

Journal of Rheumatology

Volumn 33, Issue 5, 2006, Pages 1021-1026

  Noss, Erika H ^a   Hausner Sypek, Dorota L ^b   Weinblatt, Michael E ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Center for Rheumatology LLP   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antibodies; Dermatomyositis; Monoclonal; Myositis; Polymyositis

Indexed keywords

AZATHIOPRINE; CD19 ANTIGEN; CREATINE KINASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MEPREDNISONE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; CD9 LYMPHOCYTE COUNT; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE FREE INTERVAL; FEMALE; HUMAN; MALE; MUSCLE DISEASE; MUSCLE STRENGTH; POLYMYOSITIS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; AZATHIOPRINE; B-LYMPHOCYTES; CREATINE KINASE; DERMATOMYOSITIS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; MUSCLE WEAKNESS; POLYMYOSITIS; PREDNISONE; TIME FACTORS;

EID: 33646446004     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lundberg I, Chung Y. Treatment and investigation of idiopathic inflammatory myopathies. Rheumatology Oxford 2000;39:7-17.
2. Oddis CV. Idiopathic inflammatory myopathies: a treatment update. Curr Rheumatol Rep 2003;5:431-6.
3. Wortmann RL. Idiopathic inflammatory diseases of muscle. In: Weisman ME, Louie JS, editors. Treatment of the rheumatic diseases. 2nd ed. Philadelphia: W.B. Saunders Company; 2001:201-16.
4. Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 1981;24:45-8.
5. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980;92:365-9.
6. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-7.
7. Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998;41:392-9.
8. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-6.
9. Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003;50:10-5.
10. Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology Oxford 2005;44:386-9.
11. Mok CC, To CH, Szeto ML. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J Rheumatol 2003;32:181-3.
12. Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000;27:2855-9.
13. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology Oxford 2004;43:491-6.
14. Shimojima Y, Gono T, Yamamoto K, et al. Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. Clin Rheumatol 2004;23:262-5.
15. Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology Oxford 2004;43:524-6.
16. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001;28:2230-7.
17. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology Oxford 2002;41:22-6.
18. Chambers SA, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 2005;14:210-4.
19. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232-9.
20. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
21. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
22. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
23. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485-9.
24. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7.
25. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32:1369-70.
26. Reimold AM, Weinblatt ME. Tachyphylaxis of intravenous immunoglobulin in refractory inflammatory myopathy. J Rheumatol 1994;21:1144-6.
27. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 2004;52:61-3.
28. Korkmaz C, Temiz G, Cetinbas F, Buyukkidan B. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology Oxford 2004;43:937-8.
29. Kuroda T, Morikawa H, Satou T, et al. A case of dermatomyositis complicated with pneumomediastinum successfully treated with cyclosporin A. Clin Rheumatol 2003;22:45-8.
30. Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology Oxford 2004;43:531-2.
31. Selva-O'Callaghan A, Martinez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarres M. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology Oxford 2004;43:1196-7.
32. Uthman I, El-Sayad J. Refractory polymyositis responding to infliximab. Rheumatology Oxford 2004;43:1198-9.
33. Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. Curr Rheumatol Rep 2003; 5:425-30.
34. Christopher-Stine L, Plotz PH. Adult inflammatory myopathies. Best Pract Res Clin Rheumatol 2004;18:331-44.
35. Dalakas MC. The future prospects in the classification, diagnosis and therapies of inflammatory myopathies: a view to the future from the "bench-to-bedside". J Neurol 2004;251:651-7.
36. Rider LG, Miller FW. Laboratory evaluation of the inflammatory myopathies. Clin Diagn Lab Immunol 1995;2:1-9.
37. Eisenstein DM, O'Gorman MR, Pachman LM. Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. J Rheumatol 1997;24:1830-2.